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SUMMARY
Biodegradable controlled-release micro-
sphere systems made with the biocompatible
biodegradable polyester excipient poly [DL
lactide-co-glycolide] constitute an exciting new
technology for drug delivery to the central ner-
vous system (CNS). The present study describes
functional observations indicating that im-
plantation of dopamine (DA) microspheres en-
capsulated within two different polymer exci-
pients into denervated, striatal tissue assures a
prolonged release of the transmitter /n v/vo.
Moreover, in this regard, the results show that
there were clear cut temporal differences in the
effect of the two DA microsphere formulations
compared in this study, probably reflecting vari-
ations in the actual composition (i.e., lactide to
glycolide ratio) of the two copolymer excipients
examined. This technology has considerable po-
tential for basic research with possible clinical
application.
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INTRODUCTION
The main neuroehemieal characteristic of
Parkinson’s disease is a marked lesion of the
nigro-striatal dopamine (DA) pathway. Current
clinical management of Parkinson’s disease relies
strongly on substitution treatment with the DA
prec.ursor L-DOPA and/or direct DA agonists,
administered via the parenteral route. In recent
years several attempts have been made to
reverse neurologically debilitating nigrostriatal
DA deficiency by different alternative means of
replacement therapy /1L Although some
advances have been reported with neuronal and
adrenal medullary tissue transplants, this
approach has not yet proven simple and effective
to compensate for the underlying DA neuronal
loss in humans with Parkinson’s disease/9-11/.
Intracerebroventrieular infusion is another
method currently being tested in experimental
Parkinsonism ]4/and in attempted replacement
therapy of certain other neurodegenerative
diseases /6/. Ideally, however, the delivery of
substitution agents should be restricted
specifically to the relevant damaged regions of
the central nervous system (CNS).
Injectable drug delivery formulations so-
called mierospheres have recently been devel-
oped, in which drugs are microencapsulated
within bioeompatible and biodegradable
copolymer exeipients like poly [DL-lactide-eo-
glyeolide] [3L These co-polymers are from the
same class of material which has been used for
nearly two decades in resorbable surgical su-
tures. The eopolymer microsphere formulation
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protects drugs from degradation and allows re-
lease of the drug from its excipient at a con-
trolled rate for prolonged periods of time (for
weeks, or even months)/3,20/. In view of its po-
tential therapeutic usefulness, we have studied
the mierosphere methodology as a means of de-
livering DA to the rat central nervous system
(CNS) in vivo. Specifically, our previous reports
have indicated the feasibility of this approach
and preliminary evidence suggested that intra-
striatally implanted DA microspheres could,
over long periods, counteract the postsynaptic
DA receptor up-regulation resulting from
unilateral 6-hydroxydopamine (6-OHDA) lesion
of ascending dopaminergic neurons /13,14/.
Thus, these initial results support the concept
that implantation of DA microspheres could
provide an advantageous method for achieving
prolonged release of functionally significant
amounts of DA into striatal tissue in vivo to
substitute for subnormal levels of the
endogenous transmitter.
Another interesting advantage of the
mierospheres is that the duration of drug release
can be modified by manipulating the "shell"
constituent copolymer biodegradation kinetics,
e.g., by changing the ratio of lactide to glycolide
in the formulation /20/. To this end, DA was
mieroeneapsulated in two copolymer excipients
having different lactide to glycolide molar ratios.
The object of this report is to compare these 2
different copolymer formulations. This is
accomplished by comparing the duration of time
that these intrastriatally implanted DA
microspheres are able to reduce the extent of
DA agonist-induced rotational behavior in
unilaterally 6-OHDA-lesioned rats, used as a
functional index of postsynaptic DA receptor
denervation supersensitivity.
MATERIALSAND METHODS
Animals, surgery and behavioral testing
Twenty five male Sprague-Dawley rats (200-
250 g; AB Laboratorietjtinst, Sollentuna,
Sweden) were unilaterally lesioned in the
ascending median forebrain bundle (MFB) of
monoamine neurons (coordinates A-P -4.3,
L+ 1.4, D-V-8.7 from bregma, midline, and top
of skull, respectively)/16/. The neurotoxin used
for the purpose was 6-hydroxydopamine x HCI
(6-OHDA; Sigma, St Louis, MO, USA), adminis-
tered in a dose of 8 /xg/4 1 saline vehicle
(containing 0.1% ascorbate). Two weeks after
lesion, the rats were challenged with the classical
DA agonist apomorphine (0.1 mg/kg s.c.) and
rotational responses were monitored in a com-
puterized rotometer set-up /13/. Only rats in
which the DA denervation has been successful
(_> 90% striatalDA depletion) will display strong
contralateral rotation to apomorphine challenge
in this model /8,21L Rats responding to apo-
morphine with less than 400 contralateral rota-
tions per 60 rain within the first two weeks of
testing were eliminated from the study (n 7).
Testing of the remaining 18 positive responders
was then continued on a weekly basis until a
stable level of rotation was established (max
10% difference between three consecutive ses-
sions). This criterion was typically met about 6
weeks after the initial testing session (data not
shown).
Polymers employed for encapsulation ofDA
DA was encapsulated in two types of
copolymer excipient. One copolymer had a 50:50
molar ratio of lactide to glycolide (referred to as
DA 50:50). The other copolymer had a 65:35
molar ratio of lactide to glyeolide (DA 65:35). It
was predicted that, because of its higher lactide
content, the 65:35 copolymer will take longer to
biodegrade than the 50:50 eopolymer, thus
potentially affording a longer duration of
delivery ofDA in vivo.
Implantation ofDA mierospheres
Once rats reached a stable rotational baseline
level to DA agonist challenge (el. above) they
were stereotaxically injected under light ether
anesthesia with a suspension of DA micro-
spheres (prepared immediately prior to
injection). DA 50:50 microspheres (n 5; 15 mg
microspheres/50 1 saline) or DA 65:35
mierospheres (n = 9; 30 mg microspheres/50/l)
were implanted into two sites (3/l-deposits, 2
levels/site) in the mediocentral striatum (A-P +
0.7, L 2.3, D-V -4.5 and -5.5; A-P + 0.2, L 2.3, D-
V-4.5 and -.5.5)/16/. DA 50:50 is predicted to
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biodegrade twice as fast as DA 65:35 /13/. To
ensure that similar amounts of DA would be
released per unit time the quantity of DA 65:35
microspheres was therefore twice that of the DA
50:50 microspheres. A separate group of control
rats (n 4) received corresponding injections of
empty microspheres (50:50 polymer formulation;
30 mg microspheres/50/1 saline).
The injections were performed with a 10
microliter glass capillary tube (calibrated at 3
microliter intervals) connected to a standard
Hamilton syringe (50/xl) via polyethylene tubing.
The entire duration of injection was 3 min/site.
Upon completion of the second infusion, the
injection cannula was left in situ for an additional
60 seconds before being slowly retracted. The
skin wound was closed with surgical dips and the
animals allowed to recover from anesthesia
(about 30-45 minutes thereafter). They were
placed into the rotometers and their behavior
recorded for the subsequent 2-3 hours. Starting
one week after implantation of the DA
mierospheres, the rats were repeatedly tested for
DA agonist-induced rotation on a weekly basis
for 6-8 weeks.
Histology
At the termination of the 6-8 week schedule
the rats were perfused with 5% glutaraldehyde
and a series of consecutive sections (10/m) of
the striatum was incubated with anti-DA
antiserum/7,12/. The immunoeytoehernistry was
performed with the standard avidin-biotin
complex method, thus allowing visualization of
tissueDA immunoreactivity.
Statistics
The data are presented as the total number of
apomorphine-induced contralateral rotations
summed over 60 minutes, means +_ SEM.
Statistical comparisons between post-
implantation responses and pre-implantation
baseline values (= obtained in the last
apomorphine test session before implantation)
were made employing Student’s paired t-test.
The results were expressed as the mean and
standard error of the mean (SEM). Probability
levels of 5% or less were considered statistically
significant.
RFULTS
Acute rotational response to DA microsphere
implantation
The 18 rats selected for microsphere
implantation experiments had responded with
the typical "two-peak" contralateral rotation
pattern when initially challenged with apo-
morphine (0.1 mg/kg s.c.), a reliable indicator of
> 90% DA lesion success/8,21L As previously
reported /14/, upon recovery from ether
anesthesia (= 30-45 min after intrastriatal
implantation ofDA microspheres) rats exhibited
immediate contralateral rotational behavior with
an amplitude comparable to that of apomor-
phine (0.1 mg/kg s.c.) but with longer duration.
Rats receiving DA 65:35 mierospheres displayed
a somewhat more protracted response to the
microsphere implantation but had a peak rota-
tion amplitude similar to the DA 50:50 micro-
sphere group /14/. Animals implanted with
empty mierospheres did not display rotational
behavior.
Rotational responses to apomorphine in
microsphere-implanted rats
DA
DA 50:50 implants
The total number of pre-implantation contra-
lateral rotations for this group of rats was 553 +_.
58 (n 5). When compared to this value, the
central striatal DA 50:50 microsphere implants
resulted in a reduction to 397 +_ 19, a 29%
decrease in the total number of apomorphine-
induced contralateral rotations 4 weeks post-
implantation. During the subsequent two weeks
the response to apomorphine challenge slowly
approached the pre-microsphere baseline (Fig.
1). At 6 weeks there was a reduction to 497 _+ 48,
representing a non-significant 11% decrease in
the total number of apomorphine-induced
contralateral rotations.
DA 65:35 implants
The total number of pre-implantation contra-
lateral rotations for this group of rats was 506 +_.
26 (n 9). The DA 65:35 microspheres resulted
in a reduction to 319 +/- 43, representing a 37%
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decrease in the total number of apomorphine-
induced eontralateral rotations two weeks post-
implantation. From then on and up to 8 weeks
following implantation there was an average
reduction to 375 ___
50, corresponding to a 26.%
decrease in the total number, of apomorphine-
induced contralateral rotations (Fig. 2). Since, as
indicated above, the DA 65:35 polymer excipient
was predicted to outlast the DA 50:50, it is
interesting to note that the reduction in the
number of apomorphine rotations from week 3
through week 8 remained rather stable with the
former formulation whereas the apomorphine
response in the DA 50:50 group was no longer
significantly suppressed after week 5.
Sham implants
During the 6 week testing period post-
implantation,, rats that received empty
microspheres did not display any significant
change in the number of apomorphine-induced
contralateral rotations when compared to the
pre-implantation baseline (Fig. 3).
Immunocytochemistry
Micrographs of DA 50:50 are not presented
in this report. However, previously we demon-
strated that DA was present in DA 50:50 micro-
spheres 3 weeks after implantation /14/.-Our
immunocytochemical observation of these mi-
crospheres 6 weeks after implantation revealed
that the majority of the microspheres had bio-
degraded or were in the process of doing so.
There were, however, sparse traces of DA
immunoreactivity in some microspheres that had
not fully biodegraded. In no case was the
immunocytochemical reaction comparable to
that of DA 65:35. In the DA 65:35 implant
group, however, there were still mierospheres
containing respectable amounts of DA at 8
weeks (Fig. 4A-B). Examination of the micro-
graphs in this latter group also reveals
microspheres in the process of biodegrading at 8
weeks post-implantation (Fig. 4B). No DA
immunoreactivity was present in the micro-
spheres or in the striatal tissue, of the "sham"
800]
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DA 50:50
Implantation
0 -1 2 3 4 5 6
Weeks
Total number of apomorphine-induced contralateral rotations in 6-OHDA-treated rats before and for 6
consecutive weeks following implantation of DA 50:50 .microspheres. Bars represent the mean +_ SEM (n
5). The pre-implantation baseline value (= obtained in the last apomorphine test session before
Implantation) was 553 _+ 58. This value Is shown at time O. The number of apomorphine-induced
contralateral rotations post implantation were as follows: 1 week 331 __. 73, 2 weeks 382 +_ 59, 3 weeks
345 __. 20, 4 weeks 397 +_ 19, 5 weeks 453 +_ 30 and 6 weeks 497 +/- 48. Abscissa, time in weeks; ordinate,
accumulated contralateral rotations recorded for 60 minutes. Statistics: paired t-testp < 0.05 compared
to the pre-implantation baseline value.
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Total number of apomorphine-induced contralateral rotations in 6-OHDA-treated rats before and for 8
consecutive weeks following implantation of DA 65:35 microspheres. Bars represent the mean _+ SEM (n
9). The pre-implantation baseline value (= obtained in the last apomorphine test session before
implantation) was 506 + 26. This value is shown at time O. The number of apomorphine-induced
contralateral rotations post implantation were as follows: 1 week 290 +_ 51.2 weeks 319 __. 43. 3 weeks
364 +_. 51.5 weeks 376 _
52. 6 weeks. 375 _.+ 56. and 8 weeks 391 _+ 42. Abscissa. time in weeks;
ordinate, accumulated contralateral rotations recorded for 60 minutes. Statistics: paired t-test =p < 0.05.
=p < 0.001 compared to the pre-implantation baseline value.
microsphere-implanted rats, thus equally
upporting the specificity of the DA anffoody
action and confirming the efficiency of the 6-
OHDA lesion. Judging from routine microscopic.
examination of the injection areas in DA 50:50,
DA 65:35 and "sham"-treatcd animals, the im-
plantation of microsphcrcs into the striatum did
not appear to induce inflammatory reactions nor
to result in damage to the surrounding tissue (cf.
Fig. 4A-C). These observations suggest the bio-
compatibility of the microencapsulatcd DA
within CNS tissue.
DISCUSSION
The present investigation demonstrates that
implantation of microcncapsulatcd DA in the
mntral striatum can counteract, over substantial
Imriods of time, apomorphinc-induccd rotational
behavior in rats with chronic unilateral 6-OHDA
lesions of ascending (nigrostriatal) dopamincrgic
neurons, thereby confirming our previous pre-
liminary findings /14/. The attenuated respon-
siveness to DA agonist challenge in this
experimental model is likely to bc explained by a
down-regulation of dcncrvation-scnsitizcd
striatal postsynaptic DA receptors, following
implantation of the in vivo DA-rclcasing
microsphcrcs/13,14/. Moreover, in this regard,
the results show that there were clear cut
temporal differences in the effect of the two DA
microsphere formulations compared in this
study, reflecting variations in the actual
composition (i.e., lactidc to glycolidc ratio) of the
two copolymcr cxcipicnts examined.
The DA 50:50 and DA 65:35 cxcipients were
predicted to biodegradc at different time
intervals, while simultaneously unloading
functionally significant amounts of the polymer-
encapsulated DA. Our data suoDort the validity
of tlicsc predictions under in vivo conditions.
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Fig. 3: The number of apomorphine-induced contralateral rotations in 6-OHDA-treated rats before and for 6
consecutive weeks following implantation of empty microspheres. Bars represent the mean SEM (n 4).
The pre-implantation baseline value (= obtained in the last apomorphine test session before Implantation)
was 532 _+ 108. This value is shown at time O. The number of apomorphine-induced contralateral rotations
post implantation were as follows: 1 week 529 _+ 97, 2 weeks 460 _+ 73, 3 weeks 506 66, 4 weeks 465 _
92, 5 weeks 510 +_ 86 and 6 weeks 536 83. Abscissa, time in weeks; ordinate, accumulated
contralateral rotations recorded for 60 minutes. There was no statistical difference in the number of
contralateral rotations post-implantation compared to the pre-implantation baseline value.
Immediately after implantation into the central
striatum, both the DA 50:50 and the DA 65:35
microsphere mixtures elicited strong contra-
lateral rotation, considered to be mediated by
postsynaptic DA receptor stimulation. However,
this behavioral response vanished over a period
of about 3-4 h, tentatively due to rapid receptor
desensitization/13,14/. In the subsequent weekly
test sessions the DA 50:50 microsphere group
displayed a significantly reduced total number of
apomorphine-induced contralateral rotations up
to and including the 4th testing week post-
implantation. However, in the DA 65:35 experi-
ment the apomorphine response was reduced for
at least 8 weeks. Even at this time the response
to the DA agonist challenge was significantly
lower than the pre-implantation baseline,
suggesting that there was still enough DA
remaining to maintain a reduction of the 6-
OHDA-induced denervation supersensitivity.
This interpretation is further supported by the
immunocytochemical analysis, revealing the
persistence of microspheres with intact or near-
intact DA contents also at 8 weeks after
implantation (el. Fig. 4A-B). It is also interesting
to note in this context that the time-course and
extent of reduction in denervafion super-
sensitivity produced by implantation ofDA 65:35
microspheres is comparable with that reported
after striatal grafting of adrenal medullary
chromaffin tissue/19/.
Our results support the idea that the altered
duration ofin vivo release of encapsulated drug
from resorbable polymer excipients is a function
of the actual copolymer composition. There is
convincing evidence from in vitro experiments
that the rate of drug release from microspheres
is very sensitive to variations in the excipient
constituents /2,20/. Interestingly, this seems to
apply also in vivo, the major difference being
that in this case the time scale for microsphere
biodegradation is now weeks/months rather than
minutes/hours /20/. In the present study, the
implanted 65:35 DA microspheres resulted in a
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Fig. 4: Photomicrographs of frontal cryostat sections (10/m) o1’ the denervated stdatum after Implantation of DA
65:35 .B) or empty (C) microspheres. All the sections were incubated with anti-DA antiserum (1/500). The
sections were processed for immunocytochemistry using the standard avidin-biotin-peroxidase complex
method.
A DA 65:35 microcapules 8 weeks following implantation. Notice that the tissue on either side of the
injection tract is intact. DA microspheres depicted by the immunocytochemical reaction are still within the
striatum, x 160.
B This photomicrograph is a higher magnification of A. A number of immunoreactive DA microspheres can
be observed (arrows). There are some microcapules in the process of degrading (arrow heads), x 640.
C Empty microspheres (arrows) 6 weeks after implantation. Notice that these microspheres are totally
devoid o1 immunoreactivity, x 640.
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rather constant reduction in the apomorphine
response from week 3 through week 8. Thus, it
appears that even though the liberation of DA
from these polymers relies on hydrolytic surface
erosion in vivo, the rate of this process is
dependent on the actual exeipient composition
so as to allow reasonable control of the release in
the manufacturing step by, e.g., altering the
laetide to glycolide ratio in the copolymer. This
concept is also supported by the results with the
50:50 DA microspheres. Importantly, the pre-
sent data equally support the biocompatibility of
the mierosphere formulations. It might be sug-
gested that biodegradation through hydrolysis of
the exeipients used would be harmful to the
brain tissue. If so, it could be expected that the
striatal tissue would be damaged during the
process and thus the rats would no longer be
able to respond to apomorphine after termina-
tion of the biodegradation period. Our results
dearly demonstrate that this is not the case.
First, the immunocytoehemieal study revealed
that introduction of the mierospheres produced
minimal (if any) tissue damage (of. Fig. 4).
Secondly, the DA 50:50 animals returned to pre-
implantation baseline values, and thirdly,
animals implanted with "sham" microspheres
(without DA, but of the same shell composition)
did not display any reduction in their
apomorphine-induced rotational behavior over
the entire 6-week period studied.
The present copolymer microsphere prepar-
ations appear to compare favorably with other
reported polymeric excipient devices used in
studies aiming for sustained release of DA.
Other researchers have recently reported
functional results similar to ours, using single,
ram-thick ethylene-vinyl acetate (EV Ae) DA-
containing copolymer matrix rods or discs/5,22/.
As compared to the microsphere preparations,
these latter polymer designs inevitably cause
much more mechanical tissue damage by virtue
of their size when implanted and removed/22/;
indeed, aspiration of parts of the overlying
neoeortex was required in order to put the disc-
shaped DA-entrapping polymer in position for
release into the striatum/5/. Moreover, the EV
Ae devices are non-resorbable and while, in one
of the studies, only restricted gliosis was reported
/5/, the chronic biocompatibility also remains to
be established. Although the mierospheres used
in our studies cannot be removed once im-
planted, they cause minimal tissue damage and
no additional manipulation of the experimental
animal is necessary to get theDA within reach of
the striatal tissue.
As referred to above, the DA 50:50 micro-
sphere implants into the central portion of the
striatum resulted in a clear-cut, _> 4-week long,
blunting of the response to apomorphine chal-
lenge. In contrast, in a previous study, we found
no attenuation in the rotational response to
apomorphine 3 40 days after lateral striatalDA
50:50 mierosphere implants /14/. The present
results therefore represent another addition to
the growing list of examples of functional
heterogeneity of the striatum/15,17,18,23/.
Injectable mierosphere formulations have
earlier been demonstrated as a feasible means of
delivering drugs at intended sites of action, for
prolonged periods of time, at required rates and
in proper therapeutic doses, to targets outside
the blood brain barrier/20/. The present results
indicate that DA microsphere preparations have
the potential of being employed as a source of
transmitter replacement also within brain tissue
in vivo. These formulations allow sustained
diffusion of the microeneapsulated DA into the
CNS at a controlled rate for predetermined
periods of time, assure functional significance
and at the same time appear to remain com-
patible with the host tissue. This new "slow-
release", target-directed approach provides not
only a useful tool in basic neuroseienee but
conceivably, after completing similar experi-
ments in non-human primates, it may also be
employed in the clinical management of neuro-
degenerative illness such as Parkinson’s disease.
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